Robert Freedman1, Amanda M Olsen-Dufour2, Ann Olincy2. 1. Department of Psychiatry, University of Colorado Denver School of Medicine, Anschutz Medical Center, Mail Stop F546, Aurora, CO 80045, USA. Electronic address: robert.freedman@ucdenver.edu. 2. Department of Psychiatry, University of Colorado Denver School of Medicine, Anschutz Medical Center, Mail Stop F546, Aurora, CO 80045, USA.
Abstract
INTRODUCTION: Inhibitory sensory gating of the P50 cerebral evoked potential to paired auditory stimuli (S1, S2) is a widely used paradigm for the study of schizophrenia and related conditions. Its use to measure genetic, treatment, and developmental effects requires a metric with more stable properties than the simple ratio of the paired responses. METHODS: This study assessed the ratio P50S2μV/P50S1μV and P50S2μV co-varied for P50S1μV in all 27 independent published studies that compared schizophrenia patients with healthy controls from 2000 to 2019. The largest study from each research group was selected. The Colorado research group's studies were excluded to eliminate bias from the first report of the phenomenon. RESULTS: Across the 27 studies encompassing 1179 schizophrenia patients and 1091 healthy controls, both P50S2μV co-varied for P50S1μV and P50S2μV/P50S1μV significantly separated the patients from the controls (both P < 0.0001). Effect size for P50S2μV co-varied for P50S1μV is d' = 1.23. The normal distribution of P50S2μV co-varied for P50S1μV detected influences of maternal inflammation and effects on behavior in a recent developmental study, an emerging use for the P50 inhibitory gating measure. P50S2μV/P50S1μV was not normally distributed. Results from two multi-site NIMH genetics collaborations also support the use of P50S2μV as a biomarker. CONCLUSION: Both methods detect an abnormality of cerebral inhibition in schizophrenia with high significance across multiple independent laboratories. The normal distribution of P50S2μV co-varied for P50S1μV makes it more suitable for studies of genetic, treatment, and other influences on the development and expression of inhibitory deficits in schizophrenia.
INTRODUCTION: Inhibitory sensory gating of the P50 cerebral evoked potential to paired auditory stimuli (S1, S2) is a widely used paradigm for the study of schizophrenia and related conditions. Its use to measure genetic, treatment, and developmental effects requires a metric with more stable properties than the simple ratio of the paired responses. METHODS: This study assessed the ratio P50S2μV/P50S1μV and P50S2μV co-varied for P50S1μV in all 27 independent published studies that compared schizophreniapatients with healthy controls from 2000 to 2019. The largest study from each research group was selected. The Colorado research group's studies were excluded to eliminate bias from the first report of the phenomenon. RESULTS: Across the 27 studies encompassing 1179 schizophreniapatients and 1091 healthy controls, both P50S2μV co-varied for P50S1μV and P50S2μV/P50S1μV significantly separated the patients from the controls (both P < 0.0001). Effect size for P50S2μV co-varied for P50S1μV is d' = 1.23. The normal distribution of P50S2μV co-varied for P50S1μV detected influences of maternal inflammation and effects on behavior in a recent developmental study, an emerging use for the P50 inhibitory gating measure. P50S2μV/P50S1μV was not normally distributed. Results from two multi-site NIMH genetics collaborations also support the use of P50S2μV as a biomarker. CONCLUSION: Both methods detect an abnormality of cerebral inhibition in schizophrenia with high significance across multiple independent laboratories. The normal distribution of P50S2μV co-varied for P50S1μV makes it more suitable for studies of genetic, treatment, and other influences on the development and expression of inhibitory deficits in schizophrenia.
Authors: Holly K Hamilton; Terrance J Williams; Joseph Ventura; Leland J Jasperse; Emily M Owens; Gregory A Miller; Kenneth L Subotnik; Keith H Nuechterlein; Cindy M Yee Journal: Am J Psychiatry Date: 2017-12-05 Impact factor: 18.112
Authors: Jason R Tregellas; Deana B Davalos; Donald C Rojas; Merilyne C Waldo; Linzi Gibson; Korey Wylie; Yiping P Du; Robert Freedman Journal: Schizophr Res Date: 2007-03-02 Impact factor: 4.939
Authors: R Freedman; L E Adler; M Myles-Worsley; H T Nagamoto; C Miller; M Kisley; K McRae; E Cawthra; M Waldo Journal: Arch Gen Psychiatry Date: 1996-12
Authors: Jason R Tregellas; Jason Smucny; Josette G Harris; Ann Olincy; Keeran Maharajh; Eugene Kronberg; Lindsay C Eichman; Emma Lyons; Robert Freedman Journal: Am J Psychiatry Date: 2014-05 Impact factor: 18.112
Authors: Maureen McHugo; Pratik Talati; Kristan Armstrong; Simon N Vandekar; Jennifer Urbano Blackford; Neil D Woodward; Stephan Heckers Journal: Am J Psychiatry Date: 2019-10-18 Impact factor: 18.112
Authors: Nataliia Kozhemiako; Jun Wang; Chenguang Jiang; Zhenhe Zhou; Wei Zhu; Mei-Hua Hal; Shaun M Purcell; Jen Q Pan; Lei A Wang; Guanchen Gai; Kai Zou; Zhe Wang; Xiaoman Yu; Lin Zhou; Shen Li; Zhenglin Guo; Robert Law; James Coleman; Dimitrios Mylonas; Lu Shen; Guoqiang Wang; Shuping Tan; Shengying Qin; Hailiang Huang; Michael Murphy; Robert Stickgold; Dara Manoach Journal: Elife Date: 2022-05-17 Impact factor: 8.713
Authors: Sharon K Hunter; M Camille Hoffman; Angelo D'Alessandro; Anna Wyrwa; Kathleen Noonan; Steven H Zeisel; Amanda J Law; Robert Freedman Journal: Psychol Med Date: 2021-01-25 Impact factor: 10.592
Authors: Zachary J Williams; Peter G Abdelmessih; Alexandra P Key; Tiffany G Woynaroski Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2020-09-22